Aminoglutethimide is a widely used second line agent for the treatment of advanced postmenopausal breast cancer. It is considered to act primarily by inhibiting the aromatase enzyme but also has some inhibitory activity on desmolase. It is administered with a physiological replacement dose of glucocorticoid to prevent reflex hypothalamic/pituitary activation of the adrenal cortex following reduction in the excretion of adrenal corticoids, but also prevents the increase in androgens which occurs when Aminoglutethimide is given alone. Trilostane[(4 5 17)4,5-epoxy-3,17 dihydroxyandrost-2-ene-2-carbonitrile.] is a synthetic steroid which specifically inhibits the 3 beta-hydroxysteroid dehydrogenase, A 5:4 isomerase enzyme system and this drug will also reduce adrenal steroid output, when given concurrently with a glucocorticoid to prevent reflex ACTH stimulation. Since both drugs thus affect adrenal corticosteroid production, both may be expected to reduce circulating oestrogen levels; Aminogluthemide by aromatase inhibition and some effect on the adrenal cortex, and Trilostane by a reduction in the adrenal androgen production -the essential precursors of oestrogen in postmenopausal women (Figure 1 ).
An open multicentre phase II study conducted in the UK (Williams et al., 1987) , during 1982/3, confirmed the activity of Trilostane in postmenopausal advanced breast cancer previously reported (Beardwell et al., 1983; Wilkinson et al., 1984; Murray & Pitt, 1987 The duration of response was measured from day 1 of treatment until disease progression; if patients continued on therapy after evidence of progression this was recorded separately.
Response recording Although patients' responses were recorded according to UICC criteria they were further grouped as follows:
Responders (R) -CR and PR plus NC for a minimum of 26 weeks (Lawrence et al., 1980 
Discussion
Trilostane when given with a physiological replacement dose of Hydrocortisone inhibits the formation of adrenal steroids, including androstenedione and testosterone the precursors of oestrone and oestradiol respectively. Since this is the royal route to the formation of oestrogens in postmenopausal women, circulating oestrogens are reduced (Beardwell et al., 1985; Tueni et al., 1987) . Aminoglutethimide also produces decreased levels of circulating oestrogens but this is due to its inhibitory action on the aromatase enzyme (Santen & Misbin, 1981) . Aminoglutethimide in high doses also has adrenal steroid synthesis inhibitory activity and in this respect the two drugs are alike but Aminoglutethimide and Trilostane block different steroid synthetic enzymes. This therefore posed the question as to whether Trilostane and Aminoglutethimide conferred cross resistance to each other when used to treat postmenopausal advanced breast cancer. Theoretically the biochemical/pharmacological action of the drugs is similar but it has been shown that Aminoglutethimide when given to postmenopausal women receiving 40 mg of Hydrocortisone daily can cause lowering of oestrogen concentrations with maintained concentration of the androgen precursors (Santen & Misbin, 1981; Vermeulen, 1983) . This would then suggest that the major site of Aminoglutethimide activity is aromatase inhibition with less effect on adrenal steroid synthesis, as previously reported (Santen, 1982) -this would be confirmed if no cross resistance could be shown between the two drugs demonstrating that they act at different sites, even when Aminoglutethimide is given in high doses to exhibit any adrenal effect. This study strongly suggests that there is no cross resistance between the two drugs since some 15% of all patients who received both drugs responded to both. The response rate of patients to both drugs was essentially the same; objective response rates were 29% for Trilostane and 35% for Aminoglutethimide (95% confidence limits 15-43% and 19-51% respectively), similarly objective response rates including patients with no change for 6/12 or more, are Trilostane 37%, Aminoglutethimide 59% (95% confidence limits 22-52% and 42-76% respectively) . No evidence of treatment order effect could be discerned.
The number of patients experiencing side effects tended (P = 0.1), to be less with Trilostane than with Aminoglutethimide but a high dose of Aminoglutethimide was given.
There was no difference in side effect incidence attributed to steroid between the two drugs but the pattern of side effects attributed to each drug was markedly different. It is interesting though that some of the Trilostane upper GI side effects were associated with the concurrent administration of full doses of non-steroidal anti-inflammatory drugs, which probably compounds the gastric irritation; but when the NSAID was withdrawn although the gastric upset improved diarrhoea sometimes developed -suggesting that the diarrhoea associated with Trilostane is prostaglandin mediated and may be due to Trilostane inhibiting prostaglandin dehydrogenase (Sterling Winthrop). There is no evidence that patients who display adverse reactions to one drug will necessarily experience adverse effects on the other. This trial then clearly demonstrates that the theoretical pharmacological difference between Aminoglutethimide and Trilostane is confirmed in clinical practice and that the two drugs are true alternatives in both clinical efficacy and patients' susceptibility. In view of this it would be interesting to determine how reduced doses of Aminoglutethimide and Trilostane in combination, to minimise side effects and maximise reduction of circulating oestrogens, would perform. This study was supported by Sterling Winthrop Group Ltd.
